Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria

Pegvaliase (Palynziq®) was FDA approved in 2018 as an enzyme substitution therapy in patients with Phenylketonuria. However, various drug induced hypersensitivity adverse events (HAEs) have been reported. We present a case of Pegvaliase (Palynziq®) induced anaphylaxis and successful desensitization....

Descripción completa

Detalles Bibliográficos
Autores principales: Patrawala, Meera, Kuruvilla, Merin, Li, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063228/
https://www.ncbi.nlm.nih.gov/pubmed/32181140
http://dx.doi.org/10.1016/j.ymgmr.2020.100575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063228/
https://www.ncbi.nlm.nih.gov/pubmed/32181140
http://dx.doi.org/10.1016/j.ymgmr.2020.100575

Ejemplares similares